NanoCarry
NanoCarry is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at NanoCarry.
NanoCarry is a company.
Key people at NanoCarry.
Key people at NanoCarry.
NanoCarry Therapeutics is a clinical-stage biopharmaceutical company developing nanoparticle-based therapeutics to deliver biologics across the blood-brain barrier (BBB) for brain cancers and CNS diseases.[1][2][3] Its proprietary AxS platform uses bioengineered gold nanoparticles to hitch therapeutics like antibodies to insulin, enabling a 50-fold increase in brain delivery with 8x payload capacity, targeting unmet needs in neuro-oncology and neurodegeneration.[1][4][5] The lead product, AxS-007, addresses HER2+ breast cancer brain metastases, where existing therapies fail due to BBB impermeability, while the pipeline expands to lung cancer metastases and neurodegenerative diseases.[1][3][6] NanoCarry serves patients with limited treatment options, pharma partners for co-development, and solves the core challenge that excludes ~99% of drugs from the brain despite ~100 approved antibodies for other indications.[2][4]
Founded in 2021 from Bar-Ilan University research, the company is advancing toward IND filing, with AxS-007 selected for NCI's Nanotechnology Characterization Laboratory preclinical program to accelerate clinical trials.[3] Growth momentum includes lab validation in disease models, real-time imaging traceability, and a "plug & play" model for rapid therapeutic adaptation.[4][5]
NanoCarry emerged from over a decade of nanomedicine research at Prof. Rachela Popovtzer's nanoparticle lab at Bar-Ilan University's Faculty of Engineering in Israel.[1][3][5] Prof. Popovtzer, a global leader in nanomedicine, co-founded the company in 2021 alongside Dr. Oshra Betzer, who advanced the core technology during her doctoral and postdoctoral work under Popovtzer, and a third female co-founder, highlighting bold leadership in Israeli biotech.[1][3] The idea stemmed from solving medicine's urgent challenge: delivering large biologics like antibodies past the BBB, inspired by Popovtzer's gold nanoparticle innovations that leverage receptor-mediated transcytosis via insulin hitchhiking.[1][5]
Early traction built on extensive in-vivo studies in healthy animals, neurodegenerative models, and brain tumors, proving safe brain penetration and traceability via CT imaging.[5] A pivotal moment came in September 2024 when the NCI selected AxS-007 for its rigorous preclinical characterization program, partnering with NIST and FDA to fast-track IND-enabling studies and human trials.[3] Headquartered in Weizmann Science Park, Rehovot, Israel, NanoCarry transitioned swiftly from academic proof-of-concept to a pipeline-ready platform.[3][4][7]
NanoCarry stands out in brain therapeutics through its AxS platform, blending biology and nanotechnology for unprecedented BBB penetration:
These features address why only 1 of ~100 approved antibodies works for CNS diseases, positioning NanoCarry as a first-in-class enabler.[2][4]
NanoCarry rides the exploding demand for BBB-penetrating therapies amid rising brain cancer and CNS disease burdens, where BBB blocks 98-100% of biologics despite their peripheral efficacy.[1][2][4] Timing is ideal: HER2+ breast cancer affects 1 in 8 women, with brain metastases slashing survival due to failed treatments like Herceptin, while neurodegeneration lacks biologic options—NanoCarry extends proven antibodies to these "unreachable" sites.[1][3] Market forces favor it, including NCI/FDA acceleration, Israel's biotech ecosystem (e.g., Bar-Ilan roots), and pharma's push for CNS innovation via partnerships.[3][6][7]
The company influences the ecosystem by pioneering quantifiable, traceable nanodelivery, potentially unlocking infinite biologics for brain diseases and inspiring multidisciplinary convergence of nano-bioengineering.[2][5] Its female-led model signals shifts in innovation diversity, amplifying Israel's role in global nanomedicine.[1]
NanoCarry is primed for IND filing and Phase 1 trials with AxS-007 in 2025-2026, leveraging NCI data to target HER2+ brain metastases and expand via partnerships for lung cancer and neurodegeneration.[3][6] Trends like AI-driven nano-design, combo therapies, and CNS biologic surges will propel its plug & play platform, potentially yielding first-in-class approvals where others faltered.[4][5] Influence may evolve from academic spinout to pharma powerhouse, co-developing multidrug CNS regimens and redefining brain druggability.
From breaching the brain's defenses to life-saving reality, NanoCarry embodies scientific grit turning "impossible" delivery into patient wins.[1]
